🇺🇸 FDA
Pipeline program

SUB01423MIG, SUB01423MIG, Colesevelam-matching placebo film-coated oral tablets (Unit Dose C)., Colesevelam-matching placebo film-coated oral tablets (Unit Dose D)., DISSENTEN 2 mg compresse

F106-CT01

Phase 2 small_molecule active

Quick answer

SUB01423MIG, SUB01423MIG, Colesevelam-matching placebo film-coated oral tablets (Unit Dose C)., Colesevelam-matching placebo film-coated oral tablets (Unit Dose D)., DISSENTEN 2 mg compresse for Bile acid diarrhoea is a Phase 2 program (small_molecule) at Monte Rosa Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Monte Rosa Therapeutics
Indication
Bile acid diarrhoea
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials